Comparative Resistance Analysis Between Cirrhotic and Non-cirrhotic Treatment Experienced Patients Who Failed Treatment With a Combination of Vaniprevir (MK-7009) and Pegylated Interferon and Ribavirin (P/R)

Conference Reports for NATAP

EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom April 9-13

Back


Comparative Resistance Analysis Between Cirrhotic and Non-cirrhotic Treatment Experienced Patients Who Failed Treatment With a Combination of Vaniprevir (MK-7009) and Pegylated Interferon and Ribavirin (P/R)

	Reported by Jules Levin EASL 2014 April 9-13 London, UK Steve Ludmerer, Richard Barnard, Stuart Black, Joann Brunhoffer, Anita Howe, Peggy May Tan Hwang, Rong Liu, Amy Zhou, and Niloufar Mobashery Merck & Co., Inc., Whitehouse Station, NJ, USA